Free Trial

Acrivon Therapeutics (ACRV) SEC Filings & 10K Form

$7.95
-0.16 (-1.97%)
(As of 05/24/2024 04:00 PM ET)

Recent Acrivon Therapeutics SEC Filings

DateFilerForm TypeView
05/16/2024
5:56 PM
Acrivon Therapeutics (Issuer)
Devroe Eric (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/16/2024
5:58 PM
Acrivon Therapeutics (Issuer)
Gamelin Erick (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/16/2024
6:00 PM
Acrivon Therapeutics (Issuer)
Holm-Jorgensen Rasmus (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/16/2024
6:02 PM
Acrivon Therapeutics (Issuer)
Masson Kristina (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/16/2024
6:03 PM
Acrivon Therapeutics (Issuer)
Miller Mary (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/16/2024
6:05 PM
Acrivon Therapeutics (Issuer)
Peterson Katharine (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/16/2024
5:52 PM
Acrivon Therapeutics (Issuer)
Peterson Katharine (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
05/16/2024
5:54 PM
Acrivon Therapeutics (Issuer)
Blume-Jensen Peter (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/14/2024
7:00 AM
Acrivon Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/14/2024
6:31 AM
Acrivon Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
04/29/2024
11:15 PM
Acrivon Therapeutics (Filer)
Form EFFECT
04/26/2024
7:30 AM
Acrivon Therapeutics (Filer)
Form DEF 14A
04/26/2024
7:30 AM
Acrivon Therapeutics (Filer)
Form DEF 14A
04/26/2024
7:33 AM
Acrivon Therapeutics (Filer)
Acrivon Therapeutics (Filer)
Form DEFA14A
04/26/2024
7:36 AM
Acrivon Therapeutics (Filer)
Acrivon Therapeutics (Filer)
Form ARS
04/17/2024
3:39 PM
Acrivon Therapeutics (Filer)
Form S-3
Registration statement under Securities Act of 1933  
04/15/2024
7:53 AM
Acrivon Therapeutics (Issuer)
EDELMAN JOSEPH (Reporting)
PERCEPTIVE ADVISORS LLC (Reporting)
PERCEPTIVE LIFE SCIENCES MASTER FUND LTD (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
04/15/2024
7:21 AM
Acrivon Therapeutics (Subject)
PERCEPTIVE ADVISORS LLC (Filed by)
Form SC 13G/A
04/11/2024
3:16 PM
Acrivon Therapeutics (Subject)
RA CAPITAL MANAGEMENT, L.P. (Filed by)
Form SC 13D/A
04/09/2024
6:05 AM
Acrivon Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/29/2024
8:06 AM
Acrivon Therapeutics (Filer)
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
03/28/2024
7:00 AM
Acrivon Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/28/2024
6:36 AM
Acrivon Therapeutics (Filer)
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
03/06/2024
3:32 PM
Acrivon Therapeutics (Issuer)
Palani Santhosh (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/04/2024
7:15 AM
Acrivon Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/16/2024
4:13 PM
Acrivon Therapeutics (Issuer)
Masson Kristina (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/16/2024
4:14 PM
Acrivon Therapeutics (Issuer)
Miller Mary (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/14/2024
3:57 PM
Acrivon Therapeutics (Subject)
CITADEL ADVISORS LLC (Filed by)
Form SC 13G/A
02/14/2024
3:36 PM
Acrivon Therapeutics (Subject)
PERCEPTIVE ADVISORS LLC (Filed by)
Form SC 13G/A
02/14/2024
8:51 AM
Acrivon Therapeutics (Subject)
Marshall Wace North America L.P. (Filed by)
Form SC 13G/A
02/13/2024
2:40 PM
Acrivon Therapeutics (Subject)
Sands Capital Ventures, LLC (Filed by)
Form SC 13G/A
02/09/2024
3:37 PM
Acrivon Therapeutics (Issuer)
Magovcevic-Liebisch Ivana (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/09/2024
3:34 PM
Acrivon Therapeutics (Issuer)
Magovcevic-Liebisch Ivana (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
02/08/2024
7:27 AM
Acrivon Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/19/2024
3:24 PM
Acrivon Therapeutics (Issuer)
Miller Mary (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/16/2024
3:45 PM
Acrivon Therapeutics (Issuer)
Cuillerot Jean-Marie (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/12/2024
3:46 PM
Acrivon Therapeutics (Issuer)
Cuillerot Jean-Marie (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
01/08/2024
6:28 AM
Acrivon Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/17/2023
11:15 PM
Acrivon Therapeutics (Filer)
Form EFFECT
12/08/2023
3:21 PM
Acrivon Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/01/2023
3:35 PM
Acrivon Therapeutics (Filer)
Form S-3
Registration statement under Securities Act of 1933  
Nvidia’s Quiet $1 Trillion Pivot (Ad)

Nvidia recently added $277 billion in market cap … IN ONE DAY.

Find out details on these three critical Nvidia partners immediately.
11/16/2023
6:41 PM
Acrivon Therapeutics (Issuer)
Blume-Jensen Peter (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/16/2023
6:41 PM
Acrivon Therapeutics (Issuer)
Devroe Eric (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/16/2023
6:41 PM
Acrivon Therapeutics (Issuer)
Gamelin Erick (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/16/2023
6:42 PM
Acrivon Therapeutics (Issuer)
Holm-Jorgensen Rasmus (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/16/2023
6:42 PM
Acrivon Therapeutics (Issuer)
Masson Kristina (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/16/2023
6:43 PM
Acrivon Therapeutics (Issuer)
Miller Mary (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/09/2023
8:12 AM
Acrivon Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/09/2023
7:02 AM
Acrivon Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
10/19/2023
6:45 PM
Acrivon Therapeutics (Issuer)
Miller Mary (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/28/2023
6:13 PM
Acrivon Therapeutics (Issuer)
Miller Mary (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
09/28/2023
6:17 PM
Acrivon Therapeutics (Issuer)
Miller Mary (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/05/2023
4:23 PM
Acrivon Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/23/2023
3:19 PM
Acrivon Therapeutics (Issuer)
Blume-Jensen Peter (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/11/2023
7:25 AM
Acrivon Therapeutics (Filer)
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
08/11/2023
6:11 AM
Acrivon Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
08/11/2023
6:17 AM
Acrivon Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/28/2023
3:58 PM
Acrivon Therapeutics (Issuer)
BAUM CHARLES M (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
06/28/2023
4:06 PM
Acrivon Therapeutics (Issuer)
BAUM CHARLES M (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/28/2023
2:47 PM
Acrivon Therapeutics (Issuer)
Chione Ltd (Reporting)
Czernik Marcin (Reporting)
Hadjimichael Andreas (Reporting)
Nikolaou Anastasis (Reporting)
Smolokowski Wiaczeslaw (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/22/2023
4:02 PM
Acrivon Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/20/2023
4:15 PM
Acrivon Therapeutics (Issuer)
Chione Ltd (Reporting)
Czernik Marcin (Reporting)
Hadjimichael Andreas (Reporting)
Nikolaou Anastasis (Reporting)
Smolokowski Wiaczeslaw (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/20/2023
4:21 PM
Acrivon Therapeutics (Issuer)
Holm-Jorgensen Rasmus (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/14/2023
5:33 PM
Acrivon Therapeutics (Issuer)
Chione Ltd (Reporting)
Czernik Marcin (Reporting)
Hadjimichael Andreas (Reporting)
Nikolaou Anastasis (Reporting)
Smolokowski Wiaczeslaw (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/12/2023
11:20 AM
Acrivon Therapeutics (Subject)
Chione Ltd (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/05/2023
4:01 PM
Acrivon Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/01/2023
7:40 PM
Acrivon Therapeutics (Issuer)
Blume-Jensen Peter (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
(Data available from 1/1/2016 forward)


Related Companies and Tools

This page (NASDAQ:ACRV) was last updated on 5/27/2024 by MarketBeat.com Staff

From Our Partners